FBInvestor
Stocks / Intra-Cellular Therapies Inc
Institutional Ownership

Intra-Cellular Therapies Inc

CUSIP 46116X101COMITCIEURQ1 2026

13D / 13G Filings
30
Schedule 13D/13G on record
Beneficial Filers
10
Distinct reporting persons
Largest Stake
15.0%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

30 filings · latest Jun 5, 2025

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Jun 5, 2025Jpmorgan Chase &Amp; Co.13G/ASEC
2Feb 7, 2025Fmr LLC13G/A2.5%2.70MSEC
3Nov 12, 2024Fmr LLC13G/A10.5%SEC
4Nov 8, 2024Blackrock, Inc.13G/A5.9%6.22MSEC
5Oct 24, 2024Blackrock, Inc.13G/A5.9%6.22MSEC
6Oct 10, 2024Jpmorgan Chase & Co13G5.0%5.30MSEC
7Feb 13, 2024Vanguard Group Inc13G/A9.4%9.09MSEC
8Feb 9, 2024Wasatch Advisors LP13G/A3.8%SEC
9Feb 9, 2024Fmr LLC13G/A11.9%SEC
10Feb 8, 2024Wellington Management Group LLP13G/A1.8%1.76MSEC

20 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Intra-Cellular Therapies Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Huntington National Bank1$2.5K